VIROPHARMA $26.10

up +0.24


22/5/2013 04:22 PM  |  NASDAQ : VPHM  |  Industries : Manufacturing / Pharmaceutical and Medicine Manufacturing
12 Mo. Price Change : 31% - VPHM has outperformed the S&P 500 by 5%

Get Trend Analysis Icon Get Trend Analysis

Partner Headlines

  1. Top Mutual Funds Still Nibbling At Ocwen Financial

    Investors Business Daily

  2. ViroPharma, Inc. (VPHM) President and CEO Vincent Milano sells ...

    GuruFocus

  3. ViroPharma Inc. Reports Operating Results (10-Q)

    GuruFocus

  4. Benzinga's M&A Chatter for Wednesday September 26, 2012

    Benzinga

  5. UPDATE: J.P. Morgan Reiterates Neutral Rating, Raises PT on Viropharma

    Benzinga

  6. UPDATE: Bank of America Merrill Lynch Reiterates Neutral Rating, ...

    Benzinga

  7. ViroPharma up, FDA lifts ban

    Investors Business Daily

  8. ViroPharma, Halozyme Rise After FDA Issue Cleared Up

    Investors Business Daily

  9. UPDATE: Deutsche Bank Initiates Viropharma at Buy with PT of $37 ...

    Benzinga

  10. ViroPharma Inc. Reports Operating Results (10-Q)

    GuruFocus

  11. ViroPharma

    Investors Business Daily

  12. Health Care Sector Wrap

    FOXBusiness

  13. ViroPharma Receives FDA Approval of Cinryze

    Benzinga

  14. Health Care Sector Wrap

    FOXBusiness

  15. ViroPharma's Cinryze® (C1 esterase inhibitor [human]) Open Label ...

    Benzinga

  16. Palo Alto Investors' 5 Largest Healthcare Holdings

    Benzinga

  17. Top 4 Small-Cap Stocks In The Biotechnology Industry With The ...

    Benzinga

  18. Short interest surged on underperforming VPHM

    By SchaeffersResearch

  19. UPDATE: Oppenheimer Downgrades ViroPharma to Perform

    Benzinga

  20. Domino's Pizza, Viropharma Among Stocks Gapping Down Tuesday

    FOXBusiness

  21. Buyout Chatter Puts Watson Pharma In The Spotlight

    at IBD

  22. Traders Pounce on ViroPharma Puts After Drug-Related Setback

    By SchaeffersResearch

  23. ViroPharma

    at IBD

  24. ViroPharma Stock Tumbles As Vancocin Goes Generic

    at IBD

  25. Fast Money Picks For March 7th (PM, PAY, CNX)

    at Benzinga

  26. Notable Put Options Activity in ViroPharma

    at Benzinga

  27. ViroPharma and Halozyme Announce Positive Data of Subcutaneous ...

    at Benzinga

  28. IBD Tech Stock Screen: 5 Top Meds Start With Questcor

    at IBD

  29. IBD's Small-Cap Leaders Have Big Growth Potential

    at IBD

  30. UPDATE: Oppenheimer Raises PT to $32 on ViroPharma

    at Benzinga

  31. ViroPharma profit, sales beat

    at IBD

  32. ViroPharma Inc. Reports Operating Results (10-K)

    at GuruFocus

  33. ViroPharma Earnings Rise On Cinryze Drug Sales

    at IBD

  34. Notable Put Options Activity in ViroPharma

    at Benzinga

  35. Top 5 Small-Cap Drug Firms Include Questcor, Cubist

    at IBD

  36. JP Morgan Downgrades ACOR, ALTH, AMGN, VPHM

    at Benzinga

  37. Viropharma

    at IBD

  38. ViroPharma Sees 2012 Sales of $600-660M vs $593M Est

    at Benzinga

  39. ViroPharma Announces Appointment of Julie H. McHugh to Board of ...

    at Benzinga

  40. Best Biotech Stocks of 2011

    at Benzinga

  41. From Earlier: ViroPharma Purchases Exclusive Option to Acquire ...

    at Benzinga

  42. UPDATE: Goldman Sachs Initiates Coverage on ViroPharma at Neutral

    at Benzinga

  43. UPDATE: Piper Jaffray Raises PT on ViroPharma to $31

    at Benzinga

  44. Piper Jaffray Raises PT on ViroPharma to $31

    at Benzinga

  45. UPDATE: Bank of America Reiterates Buy, Raises PT to $32 on ViroPharma

    at Benzinga

  46. WBB Securities Upgrades ViroPharma to Strong Buy

    at Benzinga

  47. Oppenheimer Reiterates Outperform, Raises PT to $33 on ViroPharma

    at Benzinga

  48. UPDATE: Jefferies Reiterates Buy, Ups PT to $33 on ViroPharma

    at Benzinga

  49. Jefferies Raises PT on ViroPharma to $33

    at Benzinga

  50. ViroPharma Announces Approval of Modernized Labeling for Vancocin® ...

    at Benzinga
People viewing VPHM also viewed: , , , , , ,
Marketplace
Trading Center